 | | Vol. 13.24 – 21 June, 2022 |
| |
|
|
| Scientists identified the pathway by which miR-21 regulated glucose-stimulated insulin secretion utilizing mice lacking miR-21 in their β cells.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Together with the glucagon-like peptide-1 (GLP1), researchers reported that IL18 used the Na-Cl co-transporter and GLP1 receptors on β cells to trigger β cell development and insulin secretion.
[Developmental Cell] |
|
|
|
| Pancreatic acinar cells were exposed to lipopolysaccharide to induce the pancreatic cell damage, and mice were subjected to supramaximal cerulein stimulation to induce acute pancreatitis.
[Cell & Bioscience] |
|
|
|
| Investigators reported the molecular link between the increase in uncoupling protein expression in β-cells and β-cell failure by using genetically engineered mice and human islets.
[iScience] |
|
|
|
| Using human fetal pancreas samples and 3D differentiation of human pluripotent cells into pancreatic endocrine cells, the authors determined that SARS-CoV-2 receptors were expressed in precursors of insulin-producing pancreatic β-cells, rendering them permissive to SARS-CoV-2 infection.
[iScience] |
| |
|
|
| The effect of E2F2 on the proliferation and cell cycling of pancreatic cancer cells was analyzed by tissue culture and flow cytometry.
[Oncology Letters] |
|
|
|
| Researchers investigated GOT2-catalysed mitochondrial aspartate synthesis as an essential metabolic dependency for the proliferation of pancreatic tumor cells under hypoxic culture conditions.
[Nature Metabolism] |
|
|
|
|
| The authors summarize the age-related alterations, adaptations, and/or failures of β-cells at the molecular, morphological, and functional levels in mouse and human.
[Ageing Research Reviews] |
|
|
|
| A deeper understanding of the mechanisms underlying the tumor-promoting roles of autophagy as well as of the consequences of autophagy inhibition is necessary for the development of autophagy inhibition-based therapies against PDAC.
[Journal of Gastroenterology] |
|
|
|
| Scientists critically evaluate preclinical and clinical evidence on the application of PI3K/AKT/mTOR pathway targeting agents.
[Critical Reviews in Oncology/Hematology] |
|
|
|
|
| BioKey has entered into a Clinical Development Service Agreement with Rgene to guide three Rgene drug products: RGC-1501 for the treatment of non-small cell lung cancer, RGC-1502 for the treatment of pancreatic cancer, and RGC 1503 for the treatment of colorectal cancer patients.
[ABVC Biopharma, Inc. (Globe Newswire, Inc.)] |
|
|
|
| XBiotech, Inc. announced that it successfully completed the Phase I portion of its 1-BETTER study, a Phase I/II randomized, double-blind, placebo-controlled clinical study to evaluate its anti-cancer drug Natrunix in combination with chemotherapy for treating pancreatic cancer.
[XBiotech, Inc. (GlobeNewswire, Inc.)] |
|
|
|
|
| December 8 – 10, 2022
Los Angeles, California, United States |
|
|
|
|
|
| | National University of Ireland Galway – Galway, Ireland |
|
|
|
| | The Ohio State University Comprehensive Cancer Center – Columbus, Ohio, United States |
|
|
|
| | University of Bristol – Bristol, England, United Kingdom |
|
|
|
| | Francis Crick Institute – London, England, United Kingdom |
|
|
|
| | Uppsala University – Uppsala, Sweden |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
